1318SWOG:  A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517) , Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL

  • Principal Investigator: Maria Baer, MD
  • Location: UMGCCC

1565GCC: Multicenter phase 1/2 study of combination therapy with the DNA methyltransferase inhibitor decitabine and the poly ADP ribose polymerase (PARP) inhibitor talazoparib (BMN 673) for untreated acute myeloid leukemia (AML) in adult patients unfit for cytotoxic chemotherapy or relapsed/refractory AM

  • Principal Investigator: Maria Baer, MD
  • Location: UMGCCC

1567GCC: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)

  • Principal Investigator: Maria Baer, MD
  • Location: UMGCCC

1632GCC: A Phase 1/1b, Multicenter, Open-Label, Dose-Escalation Study of FT 2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

  • Principal Investigator: Maria Baer, MD
  • Location: UMGCCC

1423GCC: A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with Myelodysplastic Syndrome after Treatment with Hypomethylating Agents

  • Principal Investigator: Vu Duong, MD
  • Location: UMGCCC

1676GCC: A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

  • Principal Investigator: Vu Duong, MD
  • Location: UMGCCC

1618GCC: CARDIAC MAGNETIC RESONANCE IMAGING AND BIOMARKER TESTING FOR EVALUATING CARDIAC INJURY RESULTING FROM RADIATION THERAPY IN LUNG AND BREAST CANCER: A PILOT STUDY

  • Principal Investigator: Steven Feigenberg, MD
  • Location: UMGCCC

1649GCC: Allogeneic hematopoietic stem cell transplantation for severe aplastic anemia and other bone marrow failure syndromes using G-CSF mobilized CD34+ selected hematopoietic precursor cells co-infused with a reduced dose of non-mobilized donor T-cells

  • Principal Investigator: Nancy Hardy, MD, FACP
  • Location: UMGCCC

1652GCC:  Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199)

  • Principal Investigator: Arif Hussain, MD 
  • Location: UMGCCC

1687GCC: PARTIQoL: Prostate Advanced Radiation Technologies Investigating Quality of Life; A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer.

  • Principal Investigator: Mark Mishra, MD
  • Location: UMGCCC, Kaufman Cancer Center at UM UCH, Maryland Proton Treatment Center, Central Maryland Radiation Oncology

457GCC: A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 inhibitor, and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors

  • Principal Investigator: Edward Sausville, MD
  • Location: UMGCCC

1532GCC: Phase I Study of C6 Ceramide Nanoliposome in Patients with Advanced Solid Tumor

  • Principal Investigator: Edward Sausville, MD
  • Location: UMGCCC

AEWS1221: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

  • Principal Investigator: Teresa York, MD
  • Location: UMGCCC

Maryland Proton Center Clinical Trials (full list)